Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders

Reuters12-11

Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders

Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient's own red blood cells), in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210188416) on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590558100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590558100","market":"us","top_or_hot":-1,"title":"Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient's own red blood cells), in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210188416) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient's own red blood cells), in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210188416) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QNCX","symbol_name":"Quince Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8zNvhy:1","article_id":"2590558100","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590558100","pubTimestamp":1765400725,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP , in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QNCX":"Quince Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Quince Therapeutics报告eDSP治疗肺部和炎症性肠病的积极早期临床结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNCX":0.9},"content_text":"Quince Therapeutics Reports Positive Early Clinical Results for eDSP in Pulmonary and Inflammatory Bowel Disorders\n    \n\n        Quince Therapeutics Inc. announced the publication of early-stage clinical studies evaluating its lead asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient's own red blood cells), in pulmonary and inflammatory bowel disorders. The studies, summarized in the journal Frontiers in Drug Delivery, included patients with chronic obstructive pulmonary disease, cystic fibrosis, Crohn's disease, and ulcerative colitis. Results indicated that eDSP was associated with improved clinical outcomes, such as increased FEV1, reduced infections, and corticosteroid withdrawal, without typical corticosteroid-related toxicities. The company stated that topline results from the ongoing Phase 3 NEAT study of eDSP in Ataxia-Telangiectasia are expected in the middle of the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251210188416) on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590558100","isCrawlerRequest":true}